{"id":1732,"date":"2019-09-17T20:05:57","date_gmt":"2019-09-17T18:05:57","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1732"},"modified":"2024-05-28T14:11:27","modified_gmt":"2024-05-28T12:11:27","slug":"prett","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-moleculars-i-terapia-experimental-en-oncologia-oncobell\/prett\/","title":{"rendered":"Recerca precl\u00ednica i experimental dels tumors tor\u00e0cics (PReTT)"},"content":{"rendered":"\n
El grup PReTT es centra en l’estudi de noves estrat\u00e8gies terap\u00e8utiques en tumors tor\u00e0cics combinant investigaci\u00f3 molecular b\u00e0sica, translacional amb un enfoc orientat al pacient, i bioinform\u00e0tica, aix\u00ed com en el disseny i desenvolupament d’assajos cl\u00ednics. Pel que fa a la investigaci\u00f3 b\u00e0sica, estudiem els mecanismes pels quals les c\u00e8l\u00b7lules tumorals moren en resposta a diferents tractaments i est\u00edmuls. Analitzem les respostes tant a nivell cel\u00b7lular com del microambient tumoral, incl\u00f2s el sistema immunol\u00f2gic i l’estat metab\u00f2lic. En l’aspecte translacional, el nostre enfocament \u00e9s la validaci\u00f3 de biomarcadors de resposta al tractament i de diagn\u00f2stic per tal de millorar la gesti\u00f3 cl\u00ednica dels pacients amb tumors tor\u00e0cics. A nivell bioinform\u00e0tic, l’objectiu \u00e9s millorar l’estratificaci\u00f3 dels tumors tor\u00e0cics i la identificaci\u00f3 de tractaments potencialment innovadors adaptats a les caracter\u00edstiques moleculars de cada pacient.<\/p>\n
<\/p>\n\t\t\t\t\tPublicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t El grup ha desxifrat com i per qu\u00e8 moren les c\u00e8l\u00b7lules en condicions de falta de nutrients.<\/p>\nProyectos financiados por el Instituto de Salud Carlos III (ISCIII) y cofinanciados por el Fondo Europeo de Desarrollo Regional (FEDER): <\/p>\n\t\t\t\t\n Recerca precl\u00ednica i experimental dels tumors tor\u00e0cics (PReTT) Resum El grup PReTT es centra en l’estudi de noves estrat\u00e8gies terap\u00e8utiques en tumors tor\u00e0cics combinant investigaci\u00f3 molecular b\u00e0sica, translacional amb un enfoc orientat al pacient, i bioinform\u00e0tica, aix\u00ed com en el disseny i desenvolupament d’assajos cl\u00ednics. Pel que fa a la investigaci\u00f3 b\u00e0sica, estudiem els mecanismes […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-1732","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2024-11-12 01:27:11","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1732"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=1732"}],"version-history":[{"count":7,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1732\/revisions"}],"predecessor-version":[{"id":25759,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1732\/revisions\/25759"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=1732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n<\/em>Se\u00f1alizaci\u00f3n c\u00e9lula-c\u00e9lula y muerte celular en respuesta a la falta de nutrientes y a la inhibici\u00f3n del metabolismo tumoral
\n<\/strong>PI13\/00139. 01\/2014-09\/2017. 127.500 \u20ac. IP: Cristina Mu\u00f1oz Pinedo.
\nLas c\u00e9lulas tumorales son dependientes de la glucosa como fuente de energ\u00eda y tambi\u00e9n como fuente del carbono necesario para la producci\u00f3n de macromol\u00e9culas. Por este motivo, y tambi\u00e9n debido a varias mutaciones oncog\u00e9nicas, son m\u00e1s sensibles a la falta de glucosa que las c\u00e9lulas no transformadas. En este proyecto buscamos caracterizar respuestas intr\u00ednsecas a la falta de glucosa y al tratamiento con 2-deoxiglucosa; y mol\u00e9culas secretadas que medien la comunicaci\u00f3n c\u00e9lula-c\u00e9lula en respuesta a estos est\u00edmulos.\n\n\t\tMu\u00f1oz Pinedo, Cristina\n\t<\/h4>\n
\n\t\t\n\t\tcmunoz@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tNadal Alforja, Ernest\n\t<\/h4>\n
\n\t\t\n\t\tenadal@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\n
\n\t\tMu\u00f1oz Pinedo, Cristina\n\t<\/h4>\n
\n\t\t\n\t\tcmunoz@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tNadal Alforja, Ernest\n\t<\/h4>\n
\n\t\t\n\t\tenadal@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tIvan Mac\u00eda Vidueira\n\t<\/h4>\n
\n\t\t\n\t\timacia@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n
\n\t\t\n\t\tFacebook: “Cell Death”\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tApoList archive\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tLab MetaboList archive: Recopilaci\u00f3n\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tMarie Curie network META-CAN\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@meta_canproject\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tDeathBase\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tApored\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@apoptosislab\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@NadalErnest\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport administratiu\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tSe celebra la primera Jornada d’Innovaci\u00f3 sobre el Diagn\u00f2stic i Tractament dels Pacients amb C\u00e0ncer de Pulm\u00f3 al Campus de Bellvitge<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t16\/02\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tTroben com definir ter\u00e0pies dirigides en c\u00e0ncer de pulm\u00f3 gr\u00e0cies a una plataforma de seq\u00fcenciaci\u00f3 gen\u00e8tica<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t04\/01\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPrimer assaig cl\u00ednic d’un tractament que ataca el c\u00e0ncer de pulm\u00f3 i la met\u00e0stasi al cervell a la vegada<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/08\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn nou tractament pel c\u00e0ncer de pulm\u00f3 eleva la superviv\u00e8ncia i podria beneficiar a m\u00e9s de 6.000 pacients a l’any<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/06\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn receptor fins ara considerat promotor de mort en c\u00e8l\u00b7lules tumorals podria promoure el creixement del c\u00e0ncer de pulm\u00f3<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t28\/12\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tErnest Nadal presenta a ASCO els beneficis de tractar amb quimio-immunoter\u00e0pia als pacients amb c\u00e0ncer de pulm\u00f3 i met\u00e0stasi cerebral<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t14\/06\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn model de cuc permet estudiar els efectes adversos de la quimioter\u00e0pia m\u00e9s comuna contra els tumors s\u00f2lids i millorar-ne l’efectivitat<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t16\/02\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tSara Hijazo, premi a la millor ‘comunicaci\u00f3 oral’ al XIV\u00e8 Congr\u00e9s de C\u00e0ncer de Pulm\u00f3<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t01\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIdentifiquen dos f\u00e0rmacs amb activitat antitumoral en models precl\u00ednics de c\u00e0ncer de pleura maligne<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t20\/10\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn pas endavant en la medicina personalitzada contra el c\u00e0ncer de pleura maligne<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/03\/2021\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"